Special Issue

The Use of Nanomedicines for Site-Specific Delivery and Controlled Release

Message from the Guest Editor

Nanomedicines have been employed for site-specific delivery and controlled release due to their ability to overcome many of the limitations of traditional drug-delivery techniques. The small size of nanoparticles (typically sub-200 nanometers) allows them to evade the body's immune system and target specific cells or tissues in the body. This makes them particularly useful for delivering drugs to difficult targets in the body, such as the brain or cancer cells. In recent years, nanotechnology has been adapted for controlled release of drugs over an extended period. Additionally, nanoparticles can be designed to have a high drug loading capacity, which can help to increase the amount of drug that can be delivered to the target site. They also have the ability to protect the drug from degradation, thus increasing its bioavailability. Overall, the use of nanomedicines in site-specific delivery and controlled release has the potential to improve the safety and efficacy of drugs as well as increase patient compliance and reduce side effects. This Special Issue seeks to collate recent key scientific research under nano-inspired drug-delivery research for various types of diseases.

Guest Editor

Dr. Yaw Opoku-Damoah

Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia

Deadline for manuscript submissions

closed (15 December 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/158822

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).